Literature DB >> 3069829

Clinical disorders of the erythrocyte membrane skeleton.

M McGuire1, P Agre.   

Abstract

With advances in understanding of the biochemistry of the erythrocyte membrane skeleton, the molecular basis of some of the hereditary anemias has been determined. Distinct spectrin abnormalities have been identified in spherocytosis and elliptocytosis. Protein 4.1 variants may result in elliptocytosis or may be clinically silent. While abnormalities of other proteins have not yet been identified, it is likely that variants of ankyrin and perhaps other proteins will eventually be identified as defects in these biochemically heterogeneous disorders of blood. Proteins related to spectrin, ankyrin, and protein 4.1 have been found in multiple other tissues, including brain, lymphocytes, and connective tissue, and the role of these proteins is being studied. Identification of the functional abnormalities and molecular biology of abnormal erythrocyte membrane proteins is therefore likely to have direct relevance to understanding of other cell types and diseases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3069829

Source DB:  PubMed          Journal:  Hematol Pathol        ISSN: 0886-0238


  4 in total

1.  Flexibility of the alpha-spectrin N-terminus by EPR and fluorescence polarization.

Authors:  L Cherry; L W Fung; N Menhart
Journal:  Biophys J       Date:  2000-07       Impact factor: 4.033

Review 2.  Current problems in haematology. 2: Hereditary spherocytosis.

Authors:  J C Smedley; A J Bellingham
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

3.  Immunocytochemical study of membrane skeletons in abnormally shaped erythrocytes as revealed by a quick-freezing and deep-etching method.

Authors:  S Ohno; N Terada; Y Fujii; H Ueda; H Kuramoto; N Kamisawa
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

4.  Hereditary Elliptocytosis: A Rare Red Cell Membrane Disorder.

Authors:  Prashant Warang; Prabhakar Kedar
Journal:  Indian J Hematol Blood Transfus       Date:  2018-08-02       Impact factor: 0.900

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.